FUNDAMENTALS · Fundamentals · US Healthcare

aTyr Pharma (ATYR) Fundamentals 2026 — Revenue Analysis | SniperIQ

aTyr Pharma (ATYR) is a US-listed Healthcare company in Biotechnology with a market capitalization of $49M, trading at $0.50 on the NASDAQ. This SniperIQ fundamentals page covers aTyr Pharma's valuation, profitability (net margin -36857.4%), revenue (

90,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$49M
Net Margin-36857.4%
Revenue (FY25)
90,000

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is aTyr Pharma's market cap?

aTyr Pharma (ATYR) has a market capitalization of approximately $49M, trading at $0.50 on the NASDAQ. Market cap moves with the live share price.

What is aTyr Pharma's P/E ratio?

aTyr Pharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is aTyr Pharma?

aTyr Pharma runs a net profit margin of -36857.4%, a gross margin of -11754.7%, and an operating margin of -38573.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does aTyr Pharma generate?

aTyr Pharma reported revenue of

90,000 for fiscal year 2025, with net income of -$74M and earnings per share (EPS) of -0.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does aTyr Pharma pay a dividend?

aTyr Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is aTyr Pharma financially healthy?

aTyr Pharma carries a debt-to-equity ratio of 0.20x and a current ratio of 5.78x, with a market beta of 0.52. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is aTyr Pharma a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For aTyr Pharma (ATYR) the key facts are: market cap $49M, revenue

90,000, 52-week range 0.395-7.29. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track aTyr Pharma's full fundamentals live

Get aTyr Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Neurizon Therapeutics (NUZ) fundamentals · Mereo BioPharma Group (MREO) fundamentals · Instil Bio (TIL) fundamentals · eXoZymes (EXOZ) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons